Tissue Acquisition, Processing, and Pathology (TAPP) Core

项目总结(见说明)： 组织获取、处理和病理学核心的目标是： 回顾和分析临床试验患者的病理标本(项目1)，包括间硫蛋白水平和可能的其他肿瘤抗原的表达。 B.对正在进行和计划中的临床试验的临床标本进行处理和存档(与项目1一起)。 进行干扰素-α、抗腺病毒中和抗体、血清间皮蛋白和抗肿瘤抗体的检测(项目1) D.组织采集(包括项目1、2和3)。 E.从临床试验受试者和其他外科患者的肿瘤中建立稳定的细胞系(项目1、2和3)。 F.协助进行免疫组织化学分析 由于Carroll博士不幸去世，Michael Kalos博士将担任TAPP核心主任。董事会认证的解剖病理学家Leslie Litzky博士将专注于目标A，并继续担任她之前的指定参考病理学家的角色，以便在患者参加临床试验和审查肿瘤样本上的间硫蛋白或其他抗原表达之前确认诊断。史蒂文·阿尔贝尔达博士 执行修订后的目标C(以前建立的血清学分析)和E(细胞系建立)所需的专业知识将有助于这一核心。

PROJECT SUMMARY (See instructions): The Goals of the Tissue Acquisition, Prcoessing and Pathology Core are: A. Review and analyze pathologic specimens from clinical trial patients (with Project 1), including expression of mesothelin levels and potentially other tumor antigens. B. Process and archive clinical specimens from ongoing and planned clinical trials (with Project 1). C Perform assays for Interferon-alpha, anti-adenoviral neutralizing antibodies, serum mesothelin, and antitumor antibodies (with Project 1) D. Tissue acquisition (with Projects 1, 2 and 3). E. Establish stable cell lines from tumors derived from clinical trial subjects and other surgical patients (with Projects 1, 2, and 3). F. Assist in immunohistochemical analyses Dr. Michael Kalos will be the Director of the TAPP Core due to the unfortunate death of Dr. Carroll. Dr. Leslie Litzky, a Board-Certified Anatomic Pathologist, will focus on goal A and continue in her previous role as the designated reference pathologist for confirmation of diagnosis prior to patient enrollment in clinical trials and review of mesothelin or other antigen expression on tumor samples. Dr. Steven Albelda who has the expertise needed to perform revised Goals C (previously established serological assays) and E (cell line establishment) will assist in this core.